Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5.43M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
6.54M
-
Shares change
-
-2.4M
-
Total reported value, excl. options
-
$31.9M
-
Value change
-
-$12M
-
Put/Call ratio
-
1.75
-
Number of buys
-
17
-
Number of sells
-
-46
-
Price
-
$4.88
Significant Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q2 2021
78 filings reported holding APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q2 2021.
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.54M shares
.
Largest 10 shareholders include Versant Venture Management, LLC (1.26M shares), MORGAN STANLEY (1.02M shares), VANGUARD GROUP INC (707K shares), Redmile Group, LLC (695K shares), SG Americas Securities, LLC (598K shares), BlackRock Inc. (357K shares), KENNEDY CAPITAL MANAGEMENT, INC. (354K shares), JACOBS LEVY EQUITY MANAGEMENT, INC (157K shares), VOLORIDGE INVESTMENT MANAGEMENT, LLC (152K shares), and PDT Partners, LLC (124K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.